In 2015, Korea was struck by an outbreak of MERS, a disease caused by a coronavirus – the same family of viruses that also caused COVID-19. Protein-based vaccines are safe adjuvants, however, their low stability prevents a sufficient immune response in antibody-producing cells. Therefore, a highly stable adjuvant is required for a more balanced immune response.
Is the novel vaccine platform for MERS could be applicable to COVID-19?